Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference.

Mueller MM, Van Remoortel H, Meybohm P, Aranko K, Aubron C, Burger R, Carson JL, Cichutek K, De Buck E, Devine D, Fergusson D, Folléa G, French C, Frey KP, Gammon R, Levy JH, Murphy MF, Ozier Y, Pavenski K, So-Osman C, Tiberghien P, Volmink J, Waters JH, Wood EM, Seifried E; ICC PBM Frankfurt 2018 Group.

JAMA. 2019 Mar 12;321(10):983-997. doi: 10.1001/jama.2019.0554.

PMID:
30860564
2.

Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.

Zhang Z, Gu Q, Jaguva Vasudevan AA, Jeyaraj M, Schmidt S, Zielonka J, Perković M, Heckel JO, Cichutek K, Häussinger D, Smits SHJ, Münk C.

J Virol. 2016 Oct 28;90(22):10193-10208. doi: 10.1128/JVI.01497-16. Print 2016 Nov 15.

3.

Determinants of FIV and HIV Vif sensitivity of feline APOBEC3 restriction factors.

Zhang Z, Gu Q, Jaguva Vasudevan AA, Hain A, Kloke BP, Hasheminasab S, Mulnaes D, Sato K, Cichutek K, Häussinger D, Bravo IG, Smits SH, Gohlke H, Münk C.

Retrovirology. 2016 Jul 1;13(1):46. doi: 10.1186/s12977-016-0274-9.

4.

APOBEC4 Enhances the Replication of HIV-1.

Marino D, Perković M, Hain A, Jaguva Vasudevan AA, Hofmann H, Hanschmann KM, Mühlebach MD, Schumann GG, König R, Cichutek K, Häussinger D, Münk C.

PLoS One. 2016 Jun 1;11(6):e0155422. doi: 10.1371/journal.pone.0155422. eCollection 2016.

5.

Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors.

Hanauer JR, Gottschlich L, Riehl D, Rusch T, Koch V, Friedrich K, Hutzler S, Prüfer S, Friedel T, Hanschmann KM, Münch RC, Jost C, Plückthun A, Cichutek K, Buchholz CJ, Mühlebach MD.

Mol Ther Oncolytics. 2016 Feb 24;3:16003. doi: 10.1038/mto.2016.3. eCollection 2016.

6.

Suppressing active replication of a live attenuated simian immunodeficiency virus vaccine does not abrogate protection from challenge.

Gabriel B, Fiebig U, Hohn O, Plesker R, Coulibaly C, Cichutek K, Mühlebach MD, Bannert N, Kurth R, Norley S.

Virology. 2016 Feb;489:1-11. doi: 10.1016/j.virol.2015.11.030. Epub 2015 Dec 11.

7.

A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.

Malczyk AH, Kupke A, Prüfer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Eldin HS, Schmidt J, Vergara-Alert J, Süzer Y, Seifried J, Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, Eickmann M, Becker S, Mühlebach MD.

J Virol. 2015 Nov;89(22):11654-67. doi: 10.1128/JVI.01815-15. Epub 2015 Sep 9.

8.

A single amino acid substitution in the measles virus F₂ protein reciprocally modulates membrane fusion activity in pathogenic and oncolytic strains.

Heidmeier S, Hanauer JR, Friedrich K, Prüfer S, Schneider IC, Buchholz CJ, Cichutek K, Mühlebach MD.

Virus Res. 2014 Feb 13;180:43-8. doi: 10.1016/j.virusres.2013.12.016. Epub 2013 Dec 22.

PMID:
24368277
9.

A novel small animal model to study the replication of simian foamy virus in vivo.

Blochmann R, Curths C, Coulibaly C, Cichutek K, Kurth R, Norley S, Bannert N, Fiebig U.

Virology. 2014 Jan 5;448:65-73. doi: 10.1016/j.virol.2013.09.027. Epub 2013 Oct 18.

10.

[Special considerations for the regulation of biological medicinal products in individualised medicine. More than stratified medicine].

Müller-Berghaus J, Volkers P, Scherer J, Cichutek K.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Nov;56(11):1538-44. doi: 10.1007/s00103-013-1826-y. German.

PMID:
24170083
11.

Prototype foamy virus Bet impairs the dimerization and cytosolic solubility of human APOBEC3G.

Jaguva Vasudevan AA, Perkovic M, Bulliard Y, Cichutek K, Trono D, Häussinger D, Münk C.

J Virol. 2013 Aug;87(16):9030-40. doi: 10.1128/JVI.03385-12. Epub 2013 Jun 12.

12.

A global regulatory science agenda for vaccines.

Elmgren L, Li X, Wilson C, Ball R, Wang J, Cichutek K, Pfleiderer M, Kato A, Cavaleri M, Southern J, Jivapaisarnpong T, Minor P, Griffiths E, Sohn Y, Wood D.

Vaccine. 2013 Apr 18;31 Suppl 2:B163-75. doi: 10.1016/j.vaccine.2012.10.117. Review.

13.

DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.

Friedrich K, Hanauer JR, Prüfer S, Münch RC, Völker I, Filippis C, Jost C, Hanschmann KM, Cattaneo R, Peng KW, Plückthun A, Buchholz CJ, Cichutek K, Mühlebach MD.

Mol Ther. 2013 Apr;21(4):849-59. doi: 10.1038/mt.2013.16. Epub 2013 Feb 5.

14.

Safety assessment of biolistic DNA vaccination.

Langer B, Renner M, Scherer J, Schüle S, Cichutek K.

Methods Mol Biol. 2013;940:371-88. doi: 10.1007/978-1-62703-110-3_27. Review.

PMID:
23104355
15.

Interaction of human immunodeficiency virus type 1 Vif with APOBEC3G is not dependent on serine/threonine phosphorylation status.

Kopietz F, Jaguva Vasudevan AA, Krämer M, Muckenfuss H, Sanzenbacher R, Cichutek K, Flory E, Münk C.

J Gen Virol. 2012 Nov;93(Pt 11):2425-30. doi: 10.1099/vir.0.043273-0. Epub 2012 Aug 15.

PMID:
22894923
16.

Adherens junction protein nectin-4 is the epithelial receptor for measles virus.

Mühlebach MD, Mateo M, Sinn PL, Prüfer S, Uhlig KM, Leonard VH, Navaratnarajah CK, Frenzke M, Wong XX, Sawatsky B, Ramachandran S, McCray PB Jr, Cichutek K, von Messling V, Lopez M, Cattaneo R.

Nature. 2011 Nov 2;480(7378):530-3. doi: 10.1038/nature10639.

17.

Escape from R-peptide deletion in a γ-retrovirus.

Schneider IC, Eckhardt M, Brynza J, Collins MK, Cichutek K, Buchholz CJ.

Virology. 2011 Sep 30;418(2):85-92. doi: 10.1016/j.virol.2011.07.011. Epub 2011 Aug 10.

18.

[Clinical application of gene therapy. Previous experience and the future].

Langer B, Cichutek K.

Pharm Unserer Zeit. 2011 May;40(3):254-62. doi: 10.1002/pauz.201100421. Review. German. No abstract available.

PMID:
21698615
19.

RNAi-mediated gene silencing in tumour tissue using replication-competent retroviral vectors.

Schaser T, Wrede C, Duerner L, Sliva K, Cichutek K, Schnierle B, Buchholz CJ.

Gene Ther. 2011 Oct;18(10):953-60. doi: 10.1038/gt.2011.48. Epub 2011 Apr 7.

PMID:
21472010
20.

Mutation of a diacidic motif in SIV-PBj Nef impairs T-cell activation and enteropathic disease.

Tschulena U, Sanzenbacher R, Mühlebach MD, Berger A, Münch J, Schindler M, Kirchhoff F, Plesker R, Coulibaly C, Panitz S, Prüfer S, Muckenfuss H, Hamdorf M, Schweizer M, Cichutek K, Flory E.

Retrovirology. 2011 Mar 2;8:14. doi: 10.1186/1742-4690-8-14.

21.

Restriction of porcine endogenous retrovirus by porcine APOBEC3 cytidine deaminases.

Dörrschuck E, Fischer N, Bravo IG, Hanschmann KM, Kuiper H, Spötter A, Möller R, Cichutek K, Münk C, Tönjes RR.

J Virol. 2011 Apr;85(8):3842-57. doi: 10.1128/JVI.01880-10. Epub 2011 Feb 9.

22.

DARPins: an efficient targeting domain for lentiviral vectors.

Münch RC, Mühlebach MD, Schaser T, Kneissl S, Jost C, Plückthun A, Cichutek K, Buchholz CJ.

Mol Ther. 2011 Apr;19(4):686-93. doi: 10.1038/mt.2010.298. Epub 2011 Jan 11.

23.

Relevance of an academic GMP Pan-European vector infra-structure (PEVI).

Cohen-Haguenauer O, Creff N, Cruz P, Tunc C, Aïuti A, Baum C, Bosch F, Blomberg P, Cichutek K, Collins M, Danos O, Dehaut F, Federspiel M, Galun E, Garritsen H, Hauser H, Hildebrandt M, Klatzmann D, Merten OW, Montini E, O'Brien T, Panet A, Rasooly L, Scherman D, Schmidt M, Schweitzer M, Tiberghien P, Vandendriessche T, Ziehr H, Ylä-Herttuala S, von Kalle C, Gahrton G, Carrondo M.

Curr Gene Ther. 2010 Dec;10(6):414-22.

PMID:
21054249
24.

Comparative analysis of transduced primary human dendritic cells generated by the use of three different lentiviral vector systems.

Grabski E, Waibler Z, Schüle S, Kloke BP, Sender LY, Panitz S, Cichutek K, Schweizer M, Kalinke U.

Mol Biotechnol. 2011 Mar;47(3):262-9. doi: 10.1007/s12033-010-9340-z.

PMID:
20938757
25.

Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors.

Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, Brynza J, Schneider IC, Münch RC, Petznek H, Kontermann RE, Koehl U, Johnston IC, Keinänen K, Müller UC, Hohenadl C, Monyer H, Cichutek K, Buchholz CJ.

Nat Methods. 2010 Nov;7(11):929-35. doi: 10.1038/nmeth.1514. Epub 2010 Oct 10.

PMID:
20935652
26.

Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus.

Mühlebach MD, Schaser T, Zimmermann M, Armeanu S, Hanschmann KM, Cattaneo R, Bitzer M, Lauer UM, Cichutek K, Buchholz CJ.

Cancer Res. 2010 Oct 1;70(19):7620-9. doi: 10.1158/0008-5472.CAN-09-4650. Epub 2010 Sep 21.

27.

Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events.

Büning H, Uckert W, Cichutek K, Hawkins RE, Abken H.

Hum Gene Ther. 2010 Sep;21(9):1039-42. doi: 10.1089/hum.2010.131. No abstract available.

PMID:
20626322
28.

Functional HIV-2- and SIVsmmPBj- derived lentiviral vectors generated by a novel polymerase chain reaction-based approach.

Kloke BP, Schüle S, Mühlebach MD, Wolfrum N, Cichutek K, Schweizer M.

J Gene Med. 2010 May;12(5):446-52. doi: 10.1002/jgm.1454.

PMID:
20440755
29.

Interaction of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family member A (APOBEC3A) correlates with efficient lentivirus infection of monocytes.

Berger A, Münk C, Schweizer M, Cichutek K, Schüle S, Flory E.

J Biol Chem. 2010 Apr 16;285(16):12248-54. doi: 10.1074/jbc.M109.090977. Epub 2010 Feb 23.

30.

SIVagm containing the SHIV89.6P Envelope gene replicates poorly and is non-pathogenic.

Perković M, Norley S, Sanzenbacher R, Battenberg M, Panitz S, Coulibaly C, Flory E, Siegismund C, Münk C, Cichutek K.

Virology. 2010 Mar 30;399(1):87-97. doi: 10.1016/j.virol.2009.12.032. Epub 2010 Jan 25.

31.

[The framework is established: progress in gene therapy, cell therapy and tissue engineering medicine].

Cichutek K, Granzer U.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Jan;53(1):1-3. doi: 10.1007/s00103-009-0997-z. German. No abstract available.

PMID:
20094834
32.

Restriction of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj.

Schüle S, Kloke BP, Kaiser JK, Heidmeier S, Panitz S, Wolfrum N, Cichutek K, Schweizer M.

PLoS One. 2009 Sep 21;4(9):e7098. doi: 10.1371/journal.pone.0007098.

33.

Model structure of APOBEC3C reveals a binding pocket modulating ribonucleic acid interaction required for encapsidation.

Stauch B, Hofmann H, Perkovic M, Weisel M, Kopietz F, Cichutek K, Münk C, Schneider G.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12079-84. doi: 10.1073/pnas.0900979106. Epub 2009 Jul 6.

34.

Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases.

Zielonka J, Bravo IG, Marino D, Conrad E, Perković M, Battenberg M, Cichutek K, Münk C.

J Virol. 2009 Aug;83(15):7547-59. doi: 10.1128/JVI.00015-09. Epub 2009 May 20.

35.

Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer?

Buchholz CJ, Mühlebach MD, Cichutek K.

Trends Biotechnol. 2009 May;27(5):259-65. doi: 10.1016/j.tibtech.2009.02.002. Epub 2009 Mar 25. Review.

PMID:
19327858
36.

Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity.

Funke S, Schneider IC, Glaser S, Mühlebach MD, Moritz T, Cattaneo R, Cichutek K, Buchholz CJ.

Gene Ther. 2009 May;16(5):700-5. doi: 10.1038/gt.2009.11. Epub 2009 Feb 12.

PMID:
19212424
37.
38.

Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet.

Perkovic M, Schmidt S, Marino D, Russell RA, Stauch B, Hofmann H, Kopietz F, Kloke BP, Zielonka J, Ströver H, Hermle J, Lindemann D, Pathak VK, Schneider G, Löchelt M, Cichutek K, Münk C.

J Biol Chem. 2009 Feb 27;284(9):5819-26. doi: 10.1074/jbc.M808853200. Epub 2008 Dec 12.

39.

Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR.

Sun Y, Song M, Jäger E, Schwer C, Stevanovic S, Flindt S, Karbach J, Nguyen XD, Schadendorf D, Cichutek K.

Clin Cancer Res. 2008 Jul 1;14(13):4306-15. doi: 10.1158/1078-0432.CCR-07-4849.

40.

Targeted cell entry of lentiviral vectors.

Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ.

Mol Ther. 2008 Aug;16(8):1427-36. doi: 10.1038/mt.2008.128. Epub 2008 Jun 24.

41.

Cell entry targeting restricts biodistribution of replication-competent retroviruses to tumour tissue.

Duerner LJ, Schwantes A, Schneider IC, Cichutek K, Buchholz CJ.

Gene Ther. 2008 Nov;15(22):1500-10. doi: 10.1038/gt.2008.92. Epub 2008 May 29.

PMID:
18509380
42.

Good clinical practice in the European Union.

Barth I, Krafft H, Weber G, Keller-Stanislawski B, Cichutek K.

Hum Gene Ther. 2008 May;19(5):441-2. doi: 10.1089/hum.2008.0409. No abstract available.

PMID:
18507513
43.

Functions, structure, and read-through alternative splicing of feline APOBEC3 genes.

Münk C, Beck T, Zielonka J, Hotz-Wagenblatt A, Chareza S, Battenberg M, Thielebein J, Cichutek K, Bravo IG, O'Brien SJ, Löchelt M, Yuhki N.

Genome Biol. 2008;9(3):R48. doi: 10.1186/gb-2008-9-3-r48. Epub 2008 Mar 3.

44.

[Trends in vaccine development].

Scherer J, Hinz T, Cichutek K.

Pharm Unserer Zeit. 2008;37(1):86-92. Review. German. No abstract available.

PMID:
18081053
45.

European regulation tackles tissue engineering.

Sanzenbacher R, Dwenger A, Schuessler-Lenz M, Cichutek K, Flory E.

Nat Biotechnol. 2007 Oct;25(10):1089-91. No abstract available.

PMID:
17921987
46.

Sp1 and Sp3 regulate basal transcription of the human APOBEC3G gene.

Muckenfuss H, Kaiser JK, Krebil E, Battenberg M, Schwer C, Cichutek K, Münk C, Flory E.

Nucleic Acids Res. 2007;35(11):3784-96. Epub 2007 May 21.

47.

Multiple restrictions of human immunodeficiency virus type 1 in feline cells.

Münk C, Zielonka J, Constabel H, Kloke BP, Rengstl B, Battenberg M, Bonci F, Pistello M, Löchelt M, Cichutek K.

J Virol. 2007 Jul;81(13):7048-60. Epub 2007 Apr 25.

48.

Impact of viral accessory proteins of SIVsmmPBj on early steps of infection of quiescent cells.

Wolfrum N, Mühlebach MD, Schüle S, Kaiser JK, Kloke BP, Cichutek K, Schweizer M.

Virology. 2007 Aug 1;364(2):330-41. Epub 2007 Apr 5.

50.

Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective.

Hinz T, Buchholz CJ, van der Stappen T, Cichutek K, Kalinke U.

J Immunother. 2006 Sep-Oct;29(5):472-6. Review.

PMID:
16971803

Supplemental Content

Loading ...
Support Center